Role of Colesevelam in Combination Lipid-Lowering Therapy
Open accessThe DOI matches its Crossref record; 76 of the 78 references it cites were found in a registry or an index.
Abstract
Hyperlipidemia is associated with an increased risk of cardiovascular events; reducing low-density lipoprotein cholesterol (LDL-C), the primary target for cholesterol-lowering therapy, lowers the risk for such events. Although bile acid sequestrants were the first class of drugs to show a mortality benefit related to LDL-C lowering, statins are now considered first-line pharmacological therapy for reducing LDL-C levels because of their potency and their remarkable record of successful outcomes studies. Nevertheless, a substantial proportion of patients do not achieve LDL-C goals with statin monotherapy. In addition, because of adverse effects (primarily myopathy), some patients may be unwilling to use or unable to tolerate statin therapy at all or may not tolerate a full therapeutic statin dose. Also, statins may increase risk of new-onset diabetes in patients at high risk for diabetes. Thus, there remains a need for other lipid-lowering drugs to be used in combination with or in place of statins. The purpose of this article is to review available data from the literature on the use of colesevelam, a second-generation bile acid sequestrant, in combination with other lipid-lowering agents. Colesevelam has been studied in combination with statins, niacin, fibrates, and ezetimibe (including some three-drug combinations). An additive reduction in LDL-C was seen with all combinations. Other observed effects of colesevelam in combination with other lipid-lowering drugs include reductions in apolipoprotein (apo) B (with statins, fibrates, ezetimibe, statin plus niacin, or statin plus ezetimibe) and high-sensitivity C-reactive protein (with statins), and increases in apo A-I (with statins, ezetimibe, or statins plus niacin). Triglyceride levels remained relatively unchanged when colesevelam was combined with statins, fibrates, ezetimibe, or statin plus ezetimibe, and decreased with the triple combination of colesevelam, statin, and niacin. Colesevelam offset the negative glycemic effects of statins and niacin in subjects with insulin resistance or impaired glucose tolerance. Colesevelam was generally well tolerated when added to other lipid-lowering therapies in clinical trials, with gastrointestinal effects such as constipation being the predominant adverse events. Since colesevelam is not absorbed and works primarily in the intestine, it has a low potential for systemic metabolic drug-drug interactions with other drugs. Colesevelam has been shown to not interact with the lipid-lowering drugs lovastatin and fenofibrate; where interaction may be anticipated, separating dosing times by 4 h reduces the impact of any interaction. Available data confirms that colesevelam has additive cholesterol-lowering effects when used in combination with other lipid-lowering therapies. Furthermore, in some patient populations, the additional glucose-lowering effect of colesevelam may be beneficial in offsetting hyperglycemic effects of other lipid-lowering drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Percent reductions from baseline in low-density lipoprotein cholesterol (LDL-C) in studies evaluating colesevelam (COL) administered in combination with a statin: a COL and atorvastatin (ATO) alone and in combination [41], b COL and lovastatin (LOV) alone and in combination [40], and c COL and simvastatin (SIM) alone and in combination [42]. a p < 0.01 for all between-group comparisons. b p < 0.01 for all between-group comparisons except COL + ATO 10 mg/day vs. ATO 80 mg/day (p = 0.07). c p < 0.05 vs. placebo. d p < 0.05 vs. each monotherapy. e p < 0.0001 vs. placebo. f p ≤ 0.001 vs. each monotherapy. gCOL and LOV given together at dinner. hCOL given at dinner and LOV administered at bedtime. ATO panel adapted from Hunninghake et al. [41], with permission from Elsevier. LOV panel reproduced from Davidson et al. [40], Copyright © 2001 Wiley Periodicals, Inc., with permission from John Wiley & Sons, Inc. SIM panel adapted from Knapp et al. [42], with permission from Elsevier](https://figures.cochat.ai/paper-figures/53d93e1ee1be43d5ba4ef7048a6e4918/role-of-colesevelam-in-combination-lipid-lowering-therapy-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the risk is higher with the more potent statins at high doses [248], and is also higher in the elderly, and in the presence of other risk factors for diabetes such as overweight or insulin resistance [249].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [248]
In the citing paper
“Co-administration of ezetimibe and bile acid sequestrants (colesevelam, colestipol or cholestyramine) resulted in an additional reduction of LDL-C levels without any additional adverse effects when compared with the stable bile acid sequestrant regimen alone.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [254]
In the citing paper
“Coadministration of ezetimibe and bile acid sequestrants (colesevelam, colestipol or cholestyramine) resulted in an additional reduction of LDL-C levels without any additional adverse effects when compared with the stable bile acid sequestrant regimen alone.254”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [254]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Basevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,246
Prescribing Personalized Nutrition for Cardiovascular Health: Are We Ready?
Juma, S., Imrhan, V., Vijayagopal, P., & Prasad, C. (2014) · Lifestyle Genomics · doi:10.1159/000370213 · Cited by 1,891
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390 · cited 1×
“shown for this increased risk with statins [31, 34].”
BackgroundPearson, T. A., Laurora, I., Chu, H., & Kafonek, S. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.459 · Cited by 1,012
Kotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., & Keil, U. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60330-5 · Cited by 833
Lipid Research Clinics Program
Renfrew, R. A. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03350180015009 · Cited by 829
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
(1984) · JAMA · doi:10.1001/jama.251.3.365 · Cited by 643
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) · The Lancet · doi:10.1016/s0140-6736(10)60310-8 · Cited by 558
Goodman, D. S., Hulley, S. B., Clark, L. T., Davis, C. E., Fuster, V., LaRosa, J. C., Oberman, A., Schaefer, E. J., Steinberg, D., Brown, W. V., et al. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.148.1.36 · Cited by 529
Fonseca, V. A., Rosenstock, J., Wang, A. C., Truitt, K. E., & Jones, M. R. (2008) · Diabetes Care · doi:10.2337/dc08-0283 · Cited by 246
Self-citationKotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., Reiner, Ž., Keil, U., & EUROASPIRE Study Group (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283383f30 · Cited by 238
Pandor, A., Ara, R. M., Tumur, I., Wilkinson, A. J., Paisley, S., Duenas, A., Durrington, P. N., & Chilcott, J. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02062.x · Cited by 228
Bays, H. E., Goldberg, R. B., Truitt, K. E., & Jones, M. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.18.1975 · Cited by 212
Self-citationMeta-analysis of drug-induced adverse events associated with intensive-dose statin therapy
Silva, M., Matthews, M. L., Jarvis, C., Nolan, N. M., Belliveau, P., Malloy, M., & Gandhi, P. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.02.008 · Cited by 208
Knapp, H. H., Schrott, H., Ma, P., Knopp, R., Chin, B., Gaziano, J. M., Donovan, J. M., Burke, S. K., & Davidson, M. H. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00638-6 · Cited by 203
Goldberg, R. B. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.14.1531 · Cited by 197
Self-citationKane, J. P., Malloy, M. J., Tun, P., Phillips, N. R., Freedman, D. D., Williams, M. L., Rowe, J. S., & Havel, R. J. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101293040502 · Cited by 193
Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy
Waters, D. D., Ho, J. E., Boekholdt, S. M., DeMicco, D. A., Kastelein, J. J. P., Messig, M., Breazna, A., & Pedersen, T. R. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.042 · Cited by 178
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively
Hunninghake, D. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00437-3 · Cited by 176
Cholestyramine Resin Therapy for Hypercholesteremia: Clinical and Metabolic Studies
Hashim, S. A. (1965) · JAMA · doi:10.1001/jama.1965.03080170017004 · Cited by 171
Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met
Yan, A. T., Yan, R. T., Tan, M., Hackam, D. G., Leblanc, K. L., Kertland, H., Tsang, J. L., Jaffer, S., Kates, M. L., Leiter, L. A., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.015 · Cited by 158
Statins and Musculoskeletal Conditions, Arthropathies, and Injuries
Mansi, I., Frei, C. R., Pugh, M. J., Makris, U., & Mortensen, E. M. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6184 · Cited by 129
Statins and risk of treated incident diabetes in a primary care population
Zaharan, N. L., Williams, D., & Bennett, K. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04403.x · Cited by 123
Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients
Cham, S., Evans, M. A., Denenberg, J. O., & Golomb, B. A. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.541 · Cited by 114
Weighing the benefits of high-dose simvastatin against the risk of myopathy
Egan, A., & Colman, E. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1106689 · Cited by 113 · cited 1×
“Based on findings such as these, the US Food and Drug Administration placed limitations on the use of the 80-mg dose of simvastatin [23].”
BackgroundBays, H., Davidson, M., Jones, M. R., & Abby, S. L. (2006) · American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.039 · Cited by 103
Self-citationDavidson, M. H., Toth, P., Weiss, S., Mckenney, J., Hunninghake, D., Isaacsohn, J., Donovan, J. M., & Burke, S. K. (2001) · Clinical Cardiology · doi:10.1002/clc.4960240610 · Cited by 103
Combined therapy in the treatment of dyslipidemia
Reiner, Ž. (2010) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00764.x · Cited by 100 · cited 1×
“The author recommended that multiple drug combinations should be more widely used to potentially get more people to lipoprotein goals, even in light of the fact that cardiovascular outcomes data are lacking for such combination therapies [39].”
BackgroundDrug Interactions with Colesevelam Hydrochloride, a Novel, Potent Lipid-Lowering Agent
Donovan, J. M., Stypinski, D., Stiles, M. R., Olson, T. A., & Burke, S. K. (2000) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007831418308 · Cited by 97
Pharmacokinetics of Fluvastatin and Specific Drug Interactions
Smith, H. T., Jokubaitis, L. A., Troendle, A. J., Hwang, D. S., & Robinson, W. T. (1993) · American Journal of Hypertension · doi:10.1093/ajh/6.11.375s · Cited by 86
Parkinson, T. M., Gundersen, K., & Nelson, N. A. (1970) · Atherosclerosis · doi:10.1016/0021-9150(70)90030-4 · Cited by 81
Huijgen, R., Abbink, E. J., Bruckert, E., Stalenhoef, A. F. H., Imholz, B. P. M., Durrington, P. N., Trip, M. D., Eriksson, M., Visseren, F. L. J., Schaefer, J. R., et al. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.014 · Cited by 80
Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-9-200911030-00144 · Cited by 79 · cited 1×
“A meta-analysis indicated that the combination of statins with fibrates or ezetimibe was not associated with better clinical outcomes than high-dose statin monotherapy; limited outcomes data were available for combinations of statins with other lipid-lowering agents [36].”
BackgroundStatin myopathy: a review of recent progress
Mammen, A. L., & Amato, A. A. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833f0fc7 · Cited by 78
Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia
Glueck, C. J. (1972) · JAMA · doi:10.1001/jama.222.6.676 · Cited by 75
Danaei, G., García Rodríguez, L. A., Fernandez Cantero, O., & Hernán, M. A. (2013) · Diabetes Care · doi:10.2337/dc12-1756 · Cited by 73
Lipid-lowering effects of colesevelam HCl in combination with ezetimibe
Bays, H., Rhyne, J., Abby, S., Lai, Y.-L., & Jones, M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148436 · Cited by 58
Self-citationMcKenney, J. M., Jones, M., & Abby, S. L. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x59157 · Cited by 54
Self-citationJialal, I., Abby, S. L., Misir, S., & Nagendran, S. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2009.0007 · Cited by 33
Review: Fibrates: therapeutic review
Chapman, M. J. (2006) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/14746514060060010201 · Cited by 32
Effect of Colesevelam HCl on Single-Dose Fenofibrate Pharmacokinetics
Jones, M., Baker, B., & Mathew, P. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00006 · Cited by 30
Self-citationKnopp, R. H., Tsunehara, C. H., Retzlaff, B. M., Fish, B. E., Nguyen, H. P., Anderson, S. K., & Nguyen, T. (2006) · Metabolism · doi:10.1016/j.metabol.2006.08.013 · Cited by 28
Ryan, J. R., & Jain, A. K. (1972) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1972.tb00054.x · Cited by 26
He, L., Wickremasingha, P., Lee, J., Tao, B., Mendell-Harary, J., Walker, J., & Wight, D. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.033 · Cited by 25
Effect of Colesevelam on Lovastatin Pharmacokinetics
Donovan, J. M., Kisicki, J. C., Stiles, M. R., Tracewell, W. G., & Burke, S. K. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a144 · Cited by 25
Apparent Reduced Absorption of Gemfibrozil When Given with Colestipol
Forland, S. C., Feng, Y., & Cutler, R. E. (1990) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1990.tb03434.x · Cited by 24
Robinson, J. G., Ballantyne, C. M., Hsueh, W. A., Rosen, J., Lin, J., Shah, A. K., Lowe, R. S., Hanson, M. E., & Tershakovec, A. M. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.06.004 · Cited by 24
Brown, K. S., Armstrong, I. C., Wang, A., Walker, J. R., Noveck, R. J., Swearingen, D., Allison, M., Kissling, J. C., Kisicki, J., & Salazar, D. E. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009349378 · Cited by 24
Moore, A., Phan, B. A. P., Challender, C., Williamson, J., Marcovina, S. M., & Zhao, X.-Q. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.09.001 · Cited by 24
Drug Interaction between Simvastatin and Cholestyramine in Vitro and in Vivo.
Nakai, A., Nishikata, M., Matsuyama, K., & Ichikawa, M. (1996) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.19.1231 · Cited by 20
Bożentowicz‐Wikarek, M., Kocełak, P., Smertka, M., Olszanecka‐Glinianowicz, M., & Chudek, J. T. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70778-8 · Cited by 20
Florentin, M., Liberopoulos, E. N., Rizos, C. V., Kei, A. A., Liamis, G. L., Kostapanos, M. S., & Elisaf, M. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0103 · Cited by 19
Rautio, N., Jokelainen, J. J., Oksa, H. H., Saaristo, T., Peltonen, M., Vanhala, M. J., Puolijoki, H., Moilanen, L., Tuomilehto, J. O., Keinanen-Kiukaanniemi, S. M., et al. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001472 · Cited by 19
Angelin, B., Eriksson, M., & Einarsson, K. (1986) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1986.tb01014.x · Cited by 15
Davidson, M. H., Rooney, M., Pollock, E., Drucker, J. L., & Choy, Y. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.06.001 · Cited by 14
Metabolic changes induced in elderly patients with a cholesterol lowering resin, cholestyramine
Gherondache, C. N., & Pincus, G. (1964) · Metabolism · doi:10.1016/0026-0495(64)90039-3 · Cited by 10
Hypercholesteremia. Treatment with cholestyramine, a bile acid sequestering resin.
Casdorph, H. R. (1967) · PubMed Central · Cited by 7
He, L., Wickremasingha, P. K., Lee, J., Tao, B., Mendell‐Harary, J., Walker, J. R., & Wight, D. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.180 · Cited by 7
P2367 Effects of selected drugs on exposure to ezetimibe
Kosoglou, T. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)95361-9 · Cited by 7
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Co-administration of ezetimibe and bile acid sequestrants (colesevelam, colestipol, or cholestyramine) has been reported to result in an additional reduction of LDL-C levels by 10 20% when compared with the stable bile acid sequestrant regimen alone.(264) Coadministration of ezetimibe with PCSK9 inhibitors also result…”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Metadata
- Authors
- Jones, M. R., & Nwose, O. M.
- Affiliations
- Daiichi-Sankyo (Japan) (JP)
- Corresponding author
- Nwose, Oliseyenum M.
- Venue
- American Journal of Cardiovascular Drugs
- Published
- 2013-08-03
- Volume
- 13
- Issue
- 5
- Pages
- 315-323
- ISSN
- 1175-3277 (ISSN-L)
- 1179-187X
- PMC
- PMC3781306
- OpenAlex
- W2021668065
- Cited by
- 27
- References
- 78
- Citations by year
- 2023: 1 · 2022: 3 · 2021: 4 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 5 · 2014: 6
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Cardiovascular Drugs (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- colesevelam, bile acid sequestrants, combination lipid-lowering therapy, LDL cholesterol lowering, statins, ezetimibe, nicotinic acid, fibrates, apolipoprotein B, apolipoprotein A-I, high-sensitivity C-reactive protein, triglycerides, statin-induced diabetes, statin-induced myopathy, insulin resistance, impaired glucose tolerance, drug-drug interactions
- MeSH terms
- Colesevelam Hydrochloride, Allylamine, Anticholesteremic Agents, Drug Interactions, Drug Therapy, Combination, Humans, Hyperlipidemias, Cholesterol, LDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.